Nesiritide

At a glance

Overview

Nesiritide reproduces a hormone released by the heart in response to increased wall stress. The intravenous product Natrecor was developed to reduce congestion-related hemodynamic abnormalities and breathlessness in hospitalized heart failure. Initial studies supported short-term pressure and symptom effects, but later large-scale outcomes research changed its place in practice. ASCEND-HF did not establish a meaningful advantage for death or rehospitalization and found more hypotension. FDA subsequently withdrew the Natrecor application at the sponsor’s request because the product was no longer marketed. Its historical approval should therefore not be displayed as if it remained a currently available routine US heart-failure treatment.

Supporting sources [1] [2] [3]

How it works

Nesiritide activates natriuretic peptide receptors linked to guanylyl cyclase and increases cyclic GMP. This relaxes vascular smooth muscle, reduces preload and afterload, and can influence renal sodium handling. Hemodynamic effects may relieve congestion but can also lower systemic pressure excessively. A favorable change in filling pressure does not by itself establish improved kidney outcomes, fewer admissions, or longer survival.

Supporting sources [1] [2] [3]

The original approved role

The historical label covered acutely decompensated heart failure with breathlessness at rest or minimal activity. It described reduced pulmonary capillary wedge pressure and short-term symptomatic improvement. The product was administered intravenously under close blood-pressure monitoring, rather than as a chronic outpatient strategy for preventing heart-failure progression.

Supporting sources [1]

What ASCEND-HF clarified

In the large ASCEND-HF randomized trial, nesiritide did not significantly reduce death or heart-failure rehospitalization. Its effect on breathlessness did not meet the prespecified significance threshold, and hypotension occurred more often. The study did not confirm the earlier concern of significantly worse renal outcomes, but it also did not establish renal protection.

Supporting sources [2]

Blood pressure was a central limitation

The label contraindicated use with persistent low systolic pressure and cardiogenic shock and warned about hypotension, renal impairment, and hypersensitivity. A vasodilator can reduce filling pressure while compromising perfusion in a vulnerable patient. That competing effect is why hemodynamic monitoring and patient selection were integral to its historical use.

Supporting sources [1]

Is Natrecor still an approved US product?

FDA’s Federal Register notice lists Natrecor among applications withdrawn effective June 15, 2020, after sponsors reported that the products were no longer marketed. This administrative history should be distinguished from a claim that the hormone has no biological activity. The old label remains a historical source, not evidence of current availability.

Supporting sources [3]

Did improving filling pressure prove better survival?

No. A favorable short-term hemodynamic effect is not equivalent to improved clinical outcomes. ASCEND-HF did not establish reduced death or heart-failure rehospitalization and found more hypotension. The history of nesiritide shows why symptom, physiological and outcome endpoints must be reported separately.

Supporting sources [1] [2]